Product Information
SAXAGLIPTIN HCL 5 MG TABLET is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $1.0387 per EA under NDC 68462072730. Its NADAC has been published 155 times since Oct 18, 2023.
FDA first approved this application on Jul 31, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462072730
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SAXAGLIPTIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205994FDA Approved
7/31/2023
TE Code
AB
On Market Since
7/31/2023
Pharmacological Classes
Price Statistics
The NADAC for SAXAGLIPTIN HCL 5 MG TABLET has been published 155 times since Oct 18, 2023, and over the history we have for it it has declined 36.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0387 per EA |
|---|---|
| All-time high | $6.6735 (Jun 12, 2024) |
| All-time low | $1.0387 (Sep 23, 2026) |
| 52-week high | $3.9379 |
| 52-week low | $1.0387 |
| Median price | $3.4572 |
| Average price | $3.4333 |
| Largest weekly change | +315.1% (Apr 17, 2024) |
| Weeks tracked | 155 |
| Tracking since | Oct 18, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
SAXAGLIPTIN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dipeptidyl Peptidase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SAXAGLIPTIN HCL 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SAXAGLIPTIN HCL 5 MG TABLET, manufactured by Glenmark Pharmaceuticals Inc., USA, is $1.0387 per EA (NDC 68462072730), effective Sep 30, 2026.
How has the price of SAXAGLIPTIN HCL 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for SAXAGLIPTIN HCL 5 MG TABLET has declined 36.2%. It has been tracked across 155 weekly CMS publications since Oct 18, 2023.
What are the highest and lowest recorded NADAC prices for SAXAGLIPTIN HCL 5 MG TABLET?
Since Oct 18, 2023, the NADAC for SAXAGLIPTIN HCL 5 MG TABLET has ranged from a low of $1.0387 (Sep 23, 2026) to a high of $6.6735 (Jun 12, 2024), with a median of $3.4572 per EA.
Are there cheaper alternatives to SAXAGLIPTIN HCL 5 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as SAXAGLIPTIN HCL 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures SAXAGLIPTIN HCL 5 MG TABLET?
SAXAGLIPTIN HCL 5 MG TABLET (NDC 68462072730) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.